# Moderna Shares Rise 13% Ahead of Third-Quarter Results Friday

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/49008
Published: 2026-11-05T03:49:22.000Z
Updated: 2026-11-05T03:49:22.000Z
Section: Investing

> The WHO vaccine advisory group recommended adding mRNA-1469 to an ongoing Phase 2/3 Ebola trial. Data for a separate cancer therapy are slated for an oral presentation.

Moderna shares climbed 13.1% to close at $258.38 on Nov. 4, a sharp move ahead of the biotechnology company’s scheduled third-quarter results on Friday.

The stock’s Nov. 4 intraday high of $258.72 was 1.67% above its Oct. 21 intraday high of $254.48. On a closing basis, the Nov. 4 finish was 5.11% above the Oct. 21 close of $245.81.

The WHO Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) recommended adding Moderna’s Ebola vaccine candidate mRNA-1469 to the ongoing Tumaini trial in the Democratic Republic of the Congo. The trial is a Phase 2/3 study.

Separately, early clinical data for mRNA-2808, Moderna’s experimental multiple myeloma therapy, are slated for an oral presentation at the American Society of Hematology’s annual meeting.

Moderna is scheduled to report third-quarter results Friday, Nov. 6, and hold a conference call at 8 a.m. ET.